CGWS(SZ:002939) Zheng Quan Zhi Xing·2025-06-23 16:31Summary of Key Points Core Viewpoint - The company, Guokai Hengtai (Beijing) Medical Technology Co., Ltd., is utilizing part of its oversubscribed funds to permanently supplement its working capital, which has been approved by its board and supervisory committee, and is awaiting shareholder approval [1][5]. Group 1: Fundraising Overview - The company was approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with a net amount of RMB 843.209 million after deducting issuance costs of RMB 102.125 million [1][2]. - The funds were fully received by July 5, 2023, and are being managed in a dedicated account with a tripartite supervision agreement in place [2]. Group 2: Use of Oversubscribed Funds - The company held meetings on August 2, 2023, and August 18, 2023, to approve the use of RMB 136.5 million of oversubscribed funds for permanent working capital [2][4]. - The plan includes using RMB 68.25 million, which constitutes approximately 30% of the total oversubscribed funds, to enhance liquidity and improve financial efficiency [4]. Group 3: Compliance and Approval Process - The use of oversubscribed funds will not conflict with the implementation of fundraising investment projects and complies with relevant regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange [4][5]. - The supervisory committee has agreed that this use of funds will not harm the interests of the company or its shareholders, and the proposal is pending approval from the shareholders' meeting [5][6].